摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dimethyl-[1-(3-quinolin-6-ylmethyl-imidazo[1,2-b]pyridazin-6-yl)-piperidin-4-yl]-amine | 1185764-58-2

中文名称
——
中文别名
——
英文名称
dimethyl-[1-(3-quinolin-6-ylmethyl-imidazo[1,2-b]pyridazin-6-yl)-piperidin-4-yl]-amine
英文别名
N,N-dimethyl-1-[3-(quinolin-6-ylmethyl)imidazo[1,2-b]pyridazin-6-yl]piperidin-4-amine
dimethyl-[1-(3-quinolin-6-ylmethyl-imidazo[1,2-b]pyridazin-6-yl)-piperidin-4-yl]-amine化学式
CAS
1185764-58-2
化学式
C23H26N6
mdl
——
分子量
386.5
InChiKey
GZEODIMWKQYVOA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.6
  • 重原子数:
    29
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    49.6
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • [EN] IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-B]PYRIDAZINE POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR LA TYROSINE KINASE C-MET
    申请人:NOVARTIS AG
    公开号:WO2009106577A1
    公开(公告)日:2009-09-03
    The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).
    该发明涉及式(I)化合物及其盐,式(I)中取代基如规范中所定义,式(I)化合物在用于治疗人体或动物体内的过程中的应用,特别是涉及C-Met酪氨酸激酶介导的疾病;式(I)化合物用于制造治疗此类疾病的药物;包含式(I)化合物的药物组合物,可选地与组合伙伴一起;式(I)化合物的制备方法。
  • Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia
    申请人:Berg Stefan
    公开号:US20090233930A9
    公开(公告)日:2009-09-17
    This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    本发明涉及具有以下结构式I的新化合物,以及它们的药学上可接受的盐、组合物和使用方法。这些新化合物提供了治疗或预防认知障碍、阿尔茨海默病、神经退行性和痴呆症的方法。
  • 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES
    申请人:Furet Pascal
    公开号:US20090264406A1
    公开(公告)日:2009-10-22
    The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).
    该发明涉及公式(I)的化合物及其盐,其中取代基如规范中所定义,公式(I)的化合物在处理人体或动物身体的过程中的应用,特别是在涉及C-Met酪氨酸激酶介导的疾病方面;公式(I)的化合物用于制造治疗此类疾病的药物;包含公式(I)的化合物的药物组合物,可选地与组合伙伴一起;公式(I)的化合物的制备过程。
  • US8822468B2
    申请人:——
    公开号:US8822468B2
    公开(公告)日:2014-09-02
  • [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
    申请人:ASTRAZENECA AB
    公开号:WO2007058602A2
    公开(公告)日:2007-05-24
    [EN] This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    [FR] La présente invention concerne de nouveaux composés ayant la formule structurale I ci-dessous : et leurs sels pharmaceutiquement acceptables, des compositions et des procédés d'utilisation. Ces nouveaux composés permettent un traitement ou une prophylaxie de troubles cognitifs, de la maladie d'Alzheimer, de la neurodégénérescence et de la démence.
查看更多